Hematology Department, Institute of Biomedical Research of Salamanca, University Hospital of Salamanca, 37007 Salamanca, Spain.
Bristol Myers Squibb, Princeton,NJ 08540, USA.
Future Oncol. 2024;20(27):1993-2004. doi: 10.1080/14796694.2024.2379228. Epub 2024 Aug 14.
To assess treatment patterns and outcomes in patients with non-del(5q) lower-risk myelodysplastic syndromes. Patient medical records were reviewed in the USA, Canada (CAN), UK and the EU. Analysis included 119 patients in the USA/CAN (median age, 61.5 years) and 245 patients in the UK/EU (median age, 67.3 years). Most patients received erythropoiesis-stimulating agents (ESAs) as first-line (1L) therapy (USA/CAN: 89.0%; UK/EU: 90.2%). A substantial proportion of 1L erythropoiesis-stimulating agent-treated patients were transfusion dependent before 1L (USA/CAN: 37.1%; UK/EU: 51.2%); a small percentage of these patients achieved transfusion independence during 1L therapy (USA/CAN: 2.8%; UK/EU: 14.4%). These findings highlight an unmet need for more effective treatments among patients with non-del(5q) lower-risk myelodysplastic syndromes.
评估非 del(5q)低危骨髓增生异常综合征患者的治疗模式和结局。在美国、加拿大（CAN）、英国和欧盟审查了患者的病历。分析包括美国/加拿大的 119 名患者（中位年龄 61.5 岁）和英国/欧盟的 245 名患者（中位年龄 67.3 岁）。大多数患者接受促红细胞生成素（ESA）作为一线（1L）治疗（美国/加拿大：89.0%；英国/欧盟：90.2%）。相当一部分 1L 接受促红细胞生成素治疗的患者在 1L 之前依赖输血（美国/加拿大：37.1%；英国/欧盟：51.2%）；这些患者中有一小部分在 1L 治疗期间实现了输血独立性（美国/加拿大：2.8%；英国/欧盟：14.4%）。这些发现突出表明，非 del(5q)低危骨髓增生异常综合征患者存在未满足的治疗需求。
